Sign up Australia
Proactive Investors - Run By Investors For Investors

Viralytics targets cash injection for cancer research

The halt will remain in place until Monday 8th January 2018.
Viralytics targets cash injection for cancer research
The company's shares are in pre-open

Viralytics' (ASX:VLA) lead drug CAVATAK® harnesses the common cold virus to infect and kill cancer cells, with a market-leading body of clinical evidence across multiple cancer indications.

A global opportunity is currently being unlocked via a combination with leading in-market immunotherapies (KEYTRUDA® and YERVOY®) creating a clear path to market in area of high unmet need.

To advance the next steps, Viralytics is heading to market with a capital raising, and the ASX has granted the company a trading halt to prepare.

The halt will remain in place until the opening of trade on Monday 8th January 2018, or earlier if an announcement is made to the market.

View full VLA profile View Profile

Viralytics Timeline

Newswire
December 10 2015

Related Articles

Picture of growing facility
May 07 2018
Establishing a vertically integrated business model provides THC with the ability to optimise efficiencies in the manufacturing process.
cancer cell
February 01 2018
The highlights included successful US and European ovarian cancer studies that underlined the potential of the company’s Parsortix liquid biopsy system
researcher filling a vial
May 29 2018
ImmuPharma chairman Tim McCarthy said: "We continue to believe Lupuzor has the potential to bring a much needed treatment to Lupus sufferers around the world"

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use